Commonwealth Equity Services, LLC Aridis Pharmaceuticals, Inc. Transaction History

Commonwealth Equity Services, LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 11, 2023	BUY	$0.31 - $1.5 $22,010 - $106,500	71,000 Added 12.35%	646,000 $202,000
Q4 2022 Feb 07, 2023	BUY	$0.81 - $1.18 $6,318 - $9,204	7,800 Added 1.38%	575,000 $678,000
Q2 2022 Jul 19, 2022	SELL	$0.91 - $1.7 $9,100 - $17,000	-10,000 Reduced 1.73%	567,200 $623,000
Q1 2022 May 04, 2022	BUY	$1.33 - $2.59 $740,810 - $1.44 Million	557,000 Added 2757.43%	577,200 $1.02 Million
Q4 2021 Jan 31, 2022	BUY	$2.0 - $3.65 $40,400 - $73,730	20,200 New	20,200 $47,000

50.2K

Ticker ARDS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 17,701,600
Description
Aridis Pharmaceuticals, Inc., a late-stage biopharmaceutical company, focuses on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that is in Phase III pivotal trials for the...

Get notified when there are updates to the investment portfolio of Commonwealth Equity Services, LLC, based on Form 13F filings with the SEC.

Stay updated on Commonwealth Equity Services, LLC with notifications on news.